Head to Head Review: Zevra Therapeutics (NASDAQ:ZVRA) vs. Clarus Therapeutics (OTCMKTS:CRXTQ)

Zevra Therapeutics (NASDAQ:ZVRA) and Clarus Therapeutics (OTCMKTS:CRXTQ) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, valuation and dividends.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Zevra Therapeutics and Clarus Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zevra Therapeutics	0	2	7	0	2.78
Clarus Therapeutics	0	0	0	0	0.00

Zevra Therapeutics currently has a consensus price target of $23.33, suggesting a potential upside of 119.92%. Given Zevra Therapeutics’ stronger consensus rating and higher possible upside, equities analysts clearly believe Zevra Therapeutics is more favorable than Clarus Therapeutics.

Profitability

This table compares Zevra Therapeutics and Clarus Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Zevra Therapeutics	101.58%	51.49%	28.86%
Clarus Therapeutics	N/A	N/A	N/A

Insider & Institutional Ownership

35.0% of Zevra Therapeutics shares are held by institutional investors. 2.4% of Zevra Therapeutics shares are held by company insiders. Comparatively, 5.3% of Clarus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Zevra Therapeutics and Clarus Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zevra Therapeutics	$106.47 million	5.89	$83.23 million	$1.99	5.33
Clarus Therapeutics	N/A	N/A	N/A	N/A	N/A

Zevra Therapeutics has higher revenue and earnings than Clarus Therapeutics.

Summary

Zevra Therapeutics beats Clarus Therapeutics on 8 of the 9 factors compared between the two stocks.

About Zevra Therapeutics

Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company’s product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.

About Clarus Therapeutics

Clarus Therapeutics Holdings, Inc., a pharmaceutical company, focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen therapies for inflammatory breast disease and certain forms of breast cancer; and license agreement with The Royal Institution for the Advancement of Learning/McGill University to develop and commercialize McGill's proprietary technology designed to treat conditions associated with CoQ10 deficiencies in humans. Clarus Therapeutics Holdings, Inc. was founded in 2003 and is based in Northbrook, Illinois.